Targeting glutathione metabolism for tumor radiosensitization (Review).

Haonan Xu, Meng Du, Xiaowen Liang, Xilin Xiao, Zhiyi Chen

Abstract readReview

In one paragraph

Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haonan XuSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China.

Meng DuKey Laboratory of Medical Imaging Precision Theranostics and Radiation Protection, College of Hunan Province, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan 410004, P.R. China.

Xiaowen LiangKey Laboratory of Medical Imaging Precision Theranostics and Radiation Protection, College of Hunan Province, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan 410004, P.R. China.

Xilin XiaoSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China.

Zhiyi ChenKey Laboratory of Medical Imaging Precision Theranostics and Radiation Protection, College of Hunan Province, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan 410004, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy represents a cornerstone treatment modality in oncology and primarily mediates tumor cell death through the generation of reactive oxygen species (ROS). Nevertheless, elevated glutathione (GSH) levels within tumor cells can scavenge these ROS, thereby compromising the efficacy of radiotherapy and promoting the emergence of radioresistance. The contemporary understanding of redox regulation in cancer underscores the strategic relevance of targeting GSH metabolism in the context of radiotherapy. This review comprehensively describes the mechanisms through which GSH metabolism contributes to radioresistance and surveys novel therapeutic approaches aimed at inhibiting GSH synthesis or promoting its depletion to achieve radiosensitization. Both pharmacological compounds and nanotechnology‑enabled delivery systems have been investigated, with an emphasis on their ability to intensify oxidative stress in tumors characterized by high GSHcontent, thus potentially improving radiotherapeutic outcomes.

Indexed as

GlutathioneNeoplasmsRadiation-Sensitizing AgentsRadiation ToleranceAnimalsHumansOxidation-ReductionOxidative StressReactive Oxygen SpeciesTumor MicroenvironmentGlutathioneRadiation-Sensitizing AgentsReactive Oxygen Speciesglutathione metabolismreactive oxygen speciesredox modulationtumor microenvironmenttumor radiotherapy

Identifiers

PMID42318964

DOI10.3892/ijmm.2026.5892

PMCPMC13299187

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.